3rd Quarter - Report

CROHN'S & COLITIS FOUNDATION for CROHN'S & COLITIS FOUNDATION

Firm
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FY 2027 Funding for medical research at the NIH and CDC FY 2027 Appropriations - DoD Congressionally Directed Medical Research Program S 864/ HR 6423 Help Ensure Lower Patient Copays Act S 526 Pharmacy Benefit Manager Transparency Act HR 5509/ S 2903: Safe Step Act S 3304 / HR 5684 Medical Foods and Formula Access Act CMS - Interoperability Standards and Prior Authorization for Drugs proposed rule CMS - RFI on step therapy in Medicare CMS - Reimbursement for infused biosimilars CMS - Medicare Competitive bidding for ostomy supplies CMS - Medicaid work requirements FDA - Approvals for pediatric IBD medications HHS - FY 2027 NBPP OMB - Proposed rule on Federal grantmaking

LobbyistCovered position, as disclosed
ERIN HENNESSEY MCKEON —

Contacted: HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE

Bills named: H.R. 5684 (119th), H.R. 6423 (119th), H.R. 5509 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.